Who is the CEO of Amanta Healthcare Ltd?
- Answer Field
-
The Chairman and Managing Director of Amanta Healthcare Ltd. is Mr. Bhavesh Patel.
BAJAJ BROKING
Amanta Healthcare Limited, established in December 1994, is a pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of sterile liquid products, primarily parenteral products. The company uses advanced packaging technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) to produce both large-volume and small-volume parenterals across multiple therapeutic segments. In addition to parenterals, Amanta manufactures medical devices, including irrigation solutions, first-aid products, and eye lubricants. Its product portfolio spans fluid therapy, ophthalmic solutions, respiratory care, and diluents, with container volumes ranging from 2ml to 1000ml and a variety of closure systems to suit different applications.
The company sells its medications through both national and international sales channels, as well as through collaborations with Indian and foreign pharmaceutical companies. Amanta sells around 45 generic medicines in India through 320 distributors and stockists. The company also sends branded items to several nations, including as Africa, Latin America, and the UK. As of March 2025, the company has 1,718 personnel working on formulation, development, and quality operations. This lets the corporation make new formulations and improve the ones it already has.
For more details, visit the Amanta Healthcare IPO page.
Details | Information |
IPO Date | September 1, 2025 to September 3, 2025 |
Issue Size | 1,00,00,000 shares (aggregating up to ₹126.00 Cr) |
Price Band | ₹120 to ₹126 per share |
Lot Size | 119 shares |
Listing At | NSE BSE |
Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat
Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat
General corporate purposes
Event | Date |
---|---|
IPO Open Date | Mon, Sep 1, 2025 |
IPO Close Date | Wed, Sep 3, 2025 |
Tentative Allotment | Thu, Sep 4, 2025 |
Initiation of Refunds | Mon, Sep 8, 2025 |
Credit of Shares to Demat | Mon, Sep 8, 2025 |
Tentative Listing Date | Tue, Sep 9, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on September 3, 2025 |
₹120 to ₹126 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 119 | ₹14,994 |
Retail (Max) | 13 | 1,547 | ₹1,94,922 |
S-HNI (Min) | 14 | 1,666 | ₹2,09,916 |
S-HNI (Max) | 66 | 7,854 | ₹9,89,604 |
B-HNI (Min) | 67 | 7,973 | ₹10,04,598 |
Log in to Your Trading Account: Access your trading account through your broker’s platform.
Navigate to the IPO Section: Go to the IPO section to view active IPO listings.
Select Amanta Healthcare IPO: Find "Amanta Healthcare IPO" and click on the ‘Apply’ button.
Enter Application Details: Specify the number of lots (minimum lot size: 119 shares) and the bid price within the range of ₹120 to ₹126 per share.
Provide Your UPI ID: Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit: Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on September 3, 2025, to complete your application process.
Additional Read- How to Apply for the Amanta Healthcare IPO?
Total Assets: Grew from ₹374.06 crore in FY23 to ₹381.76 crore as of March 2025.
Total income: Reached ₹276.09 crore in FY25.
Profit After Tax (PAT): Stood at ₹10.50 crore for March 2025.
Net Worth: Recorded at ₹96.39 crore in FY25.
Reserves and Surplus: Recorded at ₹67.56 crore (March 2025), growing steadily over the years.
EBITDA: Stood at ₹61.05 crore in March 2025.
The company’s total assets have shown steady growth over the past few years, reflecting consistent expansion of its operations.
Total income has increased gradually, indicating improved business performance and market presence.
Profit after tax has remained positive, demonstrating the company’s ability to maintain profitability while managing costs effectively.
Net worth has grown steadily, highlighting strengthened financial stability and shareholder value.
Reserves and surplus have consistently increased, reflecting prudent financial management and long-term planning.
EBITDA trends show healthy operational performance, supported by efficient production and sales strategies.
Overall, the company’s performance suggests stable growth prospects, with potential for continued expansion in both domestic and international markets.
Expansion plans involve significant capital expenditure, and any delays or cost overruns in setting up new manufacturing lines may affect expected returns.
Dependence on regulatory approvals and compliance in domestic and international markets could impact the company’s operations and growth if regulations change or approvals are delayed.
The company’s established presence in both domestic and international markets, along with partnerships with pharmaceutical firms, provides scope for expanding its product reach and sales.
Planned investments in new manufacturing lines for parenterals and medical devices can enhance production capacity, support innovation, and strengthen the company’s position in the fluid therapy and medical device segments.
KPI | Values |
ROE | 12.42% |
ROCE | 13.72% |
Debt/Equity | 2.02 |
RoNW | 10.89% |
PAT Margin | 3.86% |
EBITDA Margin | 22.11% |
Price to Book Value | 3.77 |
Registrar | Lead Manager(s) |
---|---|
MUFG Intime India Pvt.Ltd. | Beeline Capital Advisors Pvt.Ltd. |
Company Address of Amanta Healthcare Ltd Amanta Healthcare Ltd. 8th Floor, Shaligram CorporatesC.J. Marg Ambli, Ahmedabad, Gujarat, 380058
Phone: 079 67777600
Email: cs@amanta.co.in
Website: https://www.amanta.co.in/
Amanta Healthcare Limited operates in the pharmaceutical and medical device sectors, focusing on the development, manufacturing, and marketing of sterile liquid products and parenterals. The company distributes its products through domestic and international channels and maintains collaborations with Indian and foreign pharmaceutical firms. Its operations cover a wide range of therapeutic segments, supported by formulation, development, and quality teams.
The company has shown steady financial growth in recent years, with gradual increases in total assets, income, and net worth. Expansion plans include the development of new manufacturing lines and continued production of existing formulations. The IPO proceeds are intended for capital expenditure and general corporate purposes.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Amanta Healthcare IPO.
Share this article:
No result found
The Chairman and Managing Director of Amanta Healthcare Ltd. is Mr. Bhavesh Patel.
The IPO is scheduled to open on September 1, 2025 and will close on September 3, 2025.
Amanta Healthcare operates in the pharmaceutical and medical device sectors. Its core business includes development, manufacturing, and marketing of sterile liquid products, mainly parenterals, and medical devices. Sustainability depends on regulatory compliance, operational efficiency, and maintaining market presence in domestic and international markets.
The issue size is 1,00,00,000 shares, aggregating up to ₹126 crore.
‘Pre-apply’ refers to submitting your application in advance through a broker’s platform before the IPO opens, allowing for early allocation within the designated subscription period.
Once the application is submitted and the UPI mandate is approved before the cut-off time, confirmation of order placement is generally available immediately on your broker’s trading platform.
The minimum lot size is 119 shares, and the minimum order corresponds to one lot.
The tentative allotment date is September 4, 2025.
The registrar for the IPO is MUFG Intime India Pvt. Ltd.
Available IPO documents do not indicate any specific governance issues or red flags related to the company’s leadership or board structure. Investors can review the company’s prospectus for detailed disclosures.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading